Tandem Diabetes Care's Tandem Mobi Receives High User Satisfaction

Tandem Diabetes Care recently shared positive results from a user satisfaction and wearability survey for its automated insulin delivery system, Tandem Mobi. Launched in the United States in February 2024, the system utilizes Control-IQ Technology to automate insulin delivery based on continuous glucose monitor (CGM) readings. The survey, conducted over six weeks, included users who formerly managed their diabetes through multiple daily injections or other insulin pumps.

An impressive 86% of participants reported satisfaction or a very high level of satisfaction with Tandem Mobi, highlighting significant improvements in their quality of life. This demonstrates a potential shift in diabetes management towards more automated and user-friendly solutions. Among respondents who transitioned from multiple daily injections, 84% felt that Mobi reduced the burden of managing diabetes, with 82% finding it easy to use. Additionally, 77% of these users experienced increased freedom in their daily lives.

Key Takeaways

86% of users satisfied with Tandem Mobi insulin delivery system.
Tandem Mobi launched in the US in February 2024.
System uses Control-IQ Technology to automate insulin delivery.
84% of prior MDI users report reduced diabetes management burden.
Tandem Mobi is currently the smallest durable automated insulin delivery system in the US.

Analysis

Tandem Diabetes Care's positive survey results on Tandem Mobi's user satisfaction and wearability could significantly boost its market share and brand reputation, especially among users transitioning from multiple daily injections or other insulin pumps. The high satisfaction rates and reported improvements in quality of life suggest a potential shift in diabetes management towards more automated and user-friendly solutions. However, the recent FDA recall of the t:connect mobile app version 2.7 highlights the critical need for robust software integration to prevent device malfunctions and user harm. This incident underscores the importance of seamless technology integration and rigorous testing in the medical device industry. Future developments will likely focus on enhancing app stability and expanding compatibility with other CGM systems, such as Abbott's FreeStyle Libre 3, to further improve user experience and safety.

Did You Know?

Control-IQ Technology: An advanced algorithm used in automated insulin delivery systems, like Tandem Mobi, which integrates with Continuous Glucose Monitors (CGMs) to adjust insulin levels automatically based on real-time glucose readings and predictive analytics to help manage diabetes more effectively.
Continuous Glucose Monitor (CGM): A device that continuously tracks glucose levels in the body throughout the day and night, providing real-time data that can be used to adjust insulin delivery and dietary intake. Examples mentioned include DexCom's G6 and G7, and Abbott's FreeStyle Libre 3.
Class I Recall: The most serious type of recall issued by the FDA, indicating that the use of a product could cause serious injuries or death. In the context of Tandem's t:connect mobile app, it was recalled due to an issue that caused pump battery drainage and shutdown, leading to 224 reported injuries.

Tandem Diabetes Care's Tandem Mobi Receives High User Satisfaction